Abstract Library

#671 Comparison of the Utility of Biochemical Markers in Predicting the Presence and Severity of Carcinoid Heart Disease

Introduction: Carcinoid heart disease (CHD) is a complication of metastatic neuroendocrine disease and is screened for using echocardiography.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Dobson R, Burgess M, Chadwick C, Vora J, Pritchard M,

Keywords: carcinoid heart, biomarker,

#582 Comparison of biomarkers in predicting presence and severity of carcinoid heart disease in patients with metastatic mid-gut neuroendocrine tumours

Introduction: Carcinoid heart disease (CHD) is evaluated using echocardiography. The utility of plasma biomarkers for detecting the presence/severity of CHD is under-explored.

Conference:

Presenting Author:

Authors: Dobson R, Burgess M, Pritchard M, Vora J, Valle J,

Keywords: carcinoid heart disease, biomarkers,

#215 Nurse Evaluation of Long-acting Somatostatin Analogue Injection Devices: A Quantitative Study

Introduction: The two major long-acting somatostatin analogues (SSA) available on the European market for the treatment of neuroendocrine tumors and acromegaly are Somatuline Autogel (SA) and Sandostatin LAR (LAR).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Adelman D, Burgess A, Davies P,

Keywords: Somatostatin analogue, injection device, nurse, preference, NET, acromegaly, Somatuline Autogel Sandostatin,

#105 A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease

Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Wong C, Burgess M, Banks M, Ardill J, Poston G,

Keywords: carcinoid disease, chromogranin A, Neurokinin A, N-Terminal Barin Naturetic Peptide, carcinoid heart disease, echocardiography,

#104 Myocardial motion abnormalities in patients with carcinoid disease without overt carcinoid heart disease

Introduction: Cardiac abnormalities occur in 15-70% of patients with carcinoid disease, typified by fibrosis of the right-sided valves. Myocardial motion abnormalities in subjects without overt carcinoid heart disease have not been previously described. Tissue Doppler Imaging (TDI) allows quantative analysis of myocardial motion. We used this technique to investigate whether myocardial motion is reduced, suggesting fibrosis, in patients with carcinoid disease.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Wong C, Burgess M, Banks M, Poston G, Cuthbertson D,

Keywords: carcinoid heart disease, tissue doppler imaging, carcinoid syndrome, metastatic carcinoid disease, echocardiography,